CBT Stock Analysis: Buy, Sell, or Hold?
CBT - Cabot Corporation
$85.19
0.26 (0.31%)
▲
5d:
-3.06%
30d:
-4.4%
90d:
+8.74%
BUY
MODERATE Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 03, 2026
0d
Get Alerted When CBT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: CBT shows positive signals but monitor for confirmation. Market pricing in 3.2% growth. Moderate conviction.
💡 BUY OPPORTUNITY: CBT shows positive signals but monitor for confirmation. Market pricing in 3.2% growth. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$108.78
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$67.55
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 11.1x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: CBT is currently trading at $85.19, which is considered oversold relative to its 30-day fair value range of $85.50 to $90.04. From a valuation perspective, the stock is trading at a premium (Forward PE: 12.2) compared to its historical average (11.1). At these levels, the market is pricing in 3.2% annual earnings growth.
Technical Outlook: Technically, CBT is in a strong uptrend. The price is currently testing key support at $84.04. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: CBT scores 66/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CBT is in a strong uptrend. The price is currently testing key support at $84.04. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: CBT scores 66/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$85.50 -
$90.04
Company Quality Score
63/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
89.0%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (66/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($91.33)
- BULLISH: Expecting earnings turnaround to 3.2% growth with 6.4% revenue growth
- BULLISH: Bottoming setup score 66/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$85.50 -
$90.04
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$84.04
Resistance Level
$89.23
Current Trend
Strong Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
12.21
Wall Street Target
$91.33
(+7.2%)
Revenue Growth (YoY)
6.4%
Earnings Growth (YoY)
-93.7%
Profit Margin
5.2%
Valuation Premium vs History
+3.2% premium
PE vs Historical
12.2 vs 11.1
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+3.2%
(market-implied from PE analysis)
1-Year Target
$87.92
(+3%)
2-Year Target
$90.73
(+7%)
3-Year Target
$93.63
(+10%)
3-Yr Target (if PE normalizes)
(PE: 12→11)
PE COMPRESSION
$85.13
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.1, Growth: 10.1%)
$186.71
(+119%)
Base:
(SPY PE: 12.2, Growth: 10.1%)
$113.57
(+33%)
Bear:
(PE: 10.4, Growth: 10.1%)
$96.54
(+13%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (24x PE), but valuation improves significantly next year (12x PE) as earnings recover.
Trailing PE: 23.86 | Current EPS (TTM): $3.56
Bull Case
$183.12
(+115%)
Analyst growth 96.0%, PE expands to 26.2
Base Case
$166.48
(+95%)
Market implied 96.0%, PE stable at 23.9
Bear Case
$57.75
(-32%)
Severe decline -20.0%, PE contracts to 20.3
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: August 21, 2026 9:54 PM ET
Data refreshes hourly during market hours. Next update: 10:54 PM
Data refreshes hourly during market hours. Next update: 10:54 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CBT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Specialty Chemicals Stocks
Top-rated stocks in Specialty Chemicals by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LIN
Linde plc Ordinary Shares |
BUY
28 analysts |
$547 | 67 BUY |
|
ECL
Ecolab Inc |
STRONG BUY
27 analysts |
$325 | 48 HOLD |
|
SHW
Sherwin-Williams Co |
BUY
28 analysts |
$390 | 43 HOLD |
|
APD
Air Products and Chemica… |
BUY
24 analysts |
$343 | 49 HOLD |
|
DD
Dupont De Nemours Inc |
STRONG BUY
16 analysts |
$170 | 55 HOLD |
